Abionic Sponsored Session: Pancreatic Stone Protein: Early and Rapid Sepsis Detection Across Patient Pathways
Includes a Live Web Event on 09/25/2025 at 8:25 AM (PDT)
Description:
This session is part of Sepsis Alliance Summit 2025.
In this sponsored session, the presenters will share a novel approach to enhance the early identification of patients who are at risk of developing sepsis by combining pancreatic stone protein (PSP), an early warning biomarker of sepsis, with commonly used Risk Assessment screening tools in ED triage. They will share recent clinical results and a planned study designed to strengthen the case for using PSP in the ED.
Target Audience:
Nurses, advanced practice providers, physicians, emergency responders, pharmacists, medical technologists, respiratory therapists, physical/occupational therapists, infection prevention specialists, data/quality specialists, and more.
Session Supporter:
Sepsis Alliance gratefully acknowledges the support of this session provided by Abionic.
Andrew Shorr, MD, MBA
Section Director, Pulmonary and Critical Care Medicine
Medstar Washington Hospital Center (MWHC)
Andrew Shorr, MD, MBA, is a distinguished American physician and professor, recognized for his significant contributions in the field of pulmonary and critical care medicine. He has been actively involved in clinical research, focusing on respiratory infections, sepsis, and antibiotic resistance. Dr. Shorr has authored numerous peer-reviewed articles and has been a prominent figure in advancing understanding and treatment of critical illnesses in the intensive care unit. Additionally, he has held leadership roles in various medical institutions and professional organizations, enhancing both clinical practice and medical education.
Evangelos J. Giamarellos-Bourboulis, MD, PhD
Professor of Internal Medicine and Infectious Diseases
Medical School of the National and Kapodistrian University of Athens
Evangelos J. Giamarellos-Bourboulis, MD, PhD, is Professor of Internal Medicine and Infectious Diseases at the Medical School of the National and Kapodistrian University of Athens since 2018. He was trained in the Immunology of Infections at the Department of Internal Medicine and Infectious Disease of Radboud University in the Netherlands. In 2012 and 2013, he served as guest Professor of the Department of Critical Care Medicine of Jena University Hospital in Germany. His main research contribution is immunomodulation in sepsis and in auto-inflammatory disorders for which he was awarded the Young Investigator Research Award by the European Society of Clinical Microbiology and Infectious Diseases. He has 538 publications in international peer-reviewed journals with more than 35,000 citations and h-index 91. He has contributed to the development of clarithromycin for immunomodulatory treatment of septic shock, the recognition of hidradenitis suppurativa (HS) as an auto-inflammatory disorder, and in the licensing of adalimumab for treatment of (HS). He is the current chairman of the European Sepsis Alliance. His main achievement is the approval of anakinra for COVID-19 pneumonia in adults by the European Medicines Agency and the Food and Drug Administration through the phase 2 and 3 trials SAVE and SAVE-MORE that he designed and conducted.
Patrick Pestalozzi, MBA
Chief Executive Officer
Abionic
Patrick Pestalozzi, MBA, is a former management consultant and Silicon Valley executive who is actively involved in the creation, financing, and development of multiple deep-tech startups. As a mentor, adviser, and coach to early-stage and mature organizations, he helps founders in the areas of growth strategies, product management, organizational design, international development, and sales performance. As a dual Swiss/U.S. citizen who speaks English, French, and German, he maintains global insight and cultural sensitivity from extensive travel and work in over 60 countries.